Harrow, Inc. (NASDAQ:HROW) Position Boosted by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 99.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,579 shares of the company's stock after purchasing an additional 12,762 shares during the quarter. Franklin Resources Inc. owned about 0.07% of Harrow worth $858,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in HROW. AlphaQuest LLC boosted its stake in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares during the last quarter. Maridea Wealth Management LLC purchased a new stake in Harrow in the fourth quarter valued at approximately $222,000. KLP Kapitalforvaltning AS acquired a new position in Harrow during the fourth quarter worth approximately $235,000. China Universal Asset Management Co. Ltd. raised its stake in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after purchasing an additional 727 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Harrow in the 3rd quarter valued at $271,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Stock Up 2.7 %

Shares of HROW stock traded up $0.64 during trading hours on Friday, reaching $23.99. The company had a trading volume of 199,238 shares, compared to its average volume of 507,907. The company has a market capitalization of $855.34 million, a P/E ratio of -25.52 and a beta of 0.46. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a twelve month low of $9.86 and a twelve month high of $59.23. The stock's fifty day simple moving average is $26.12 and its 200 day simple moving average is $35.70.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. As a group, sell-side analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HROW has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 target price on shares of Harrow in a research report on Monday, March 31st. B. Riley decreased their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.